Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
NextCure Inc
NASDAQ NXTC
Data sourced from
and
and
NextCure Inc Sales to Fixed Assets Ratio 3 year CAGR for the quarter ending March 31, 2024
NextCure Inc Sales to Fixed Assets Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. Sales to fixed assets ratio measures the revenue generated by a company relative to its fixed assets, such as property, plant, and equipment. It is calculated by dividing the revenue by the net value of fixed assets. This ratio provides insights into the efficiency of the company's fixed assets in generating sales revenue. A higher sales to fixed assets ratio suggests better sales generation from fixed assets and efficient utilization of physical infrastructure. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
NextCure Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
-
NextCure Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
-
NextCure Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2021 was 0.00, a -100.00% change year over year.
-
NextCure Inc Sales to Fixed Assets Ratio for the quarter ending March 31, 2020 was 1.75, a 1,419.44% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NXTC
| CEO | Mr. Michael S. Richman MSBA |
| IPO Date | May 9, 2019 |
| Location | United States |
| Headquarters | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email